Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Silexion advanced its lead asset SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, initiating the trial at Tel Aviv Sourasky Medical Center following regulatory approvals in Israel and Germany. To support the program and restore Nasdaq compliance, the company executed a 1-for-10 reverse stock split and closed a public offering raising approximately $2.5 million in gross proceeds.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.